Our data indicate PROM2 enhanced gemcitabine chemoresistance in vitro and in vivo, which implies that PROM2 could serve as a biomarker for co-therapy of gemcitabine and Akt inhibitors in pancreatic cancer treatment. The gene discussed is PROM2; the disease is pancreatic neoplasm.